Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL5429038 | 0.95 | CA1 (0.82) | — | |
| Acetic Acid SCHEMBL10953112 | 0.95 | CA1 (0.82) | — | |
| Acetic Acid SCHEMBL6749539 | 0.95 | CA1 (0.82) | — | |
| Acetic Acid SCHEMBL11168446 | 0.95 | CA1 (0.82) | — | |
| Acetic Acid SCHEMBL7316954 | 0.95 | CA1 (0.82) | — | |
| Acetic Acid SCHEMBL437034 | 0.95 | CA1 (0.82) | — | |
| Acetic Acid SCHEMBL11171825 | 0.95 | CA1 (0.82) | — | |
| Acetic Acid SCHEMBL10939984 | 0.95 | CA1 (0.82) | — | |
| Acetic Acid SCHEMBL11533245 | 0.95 | CA1 (0.82) | — | |
| Acetic Acid SCHEMBL6856161 | 0.95 | CA1 (0.82) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110174516-A | Goose parvovirus VP3 proteantigen ELISA detection kit and detection method and application | 扬州优邦生物药品有限公司 | 2019-08-27 | — | — | CN | disclosed |
| CN-106769965-A | A kind of method that dopamine is detected using 5 hydroxytryptamine golden nanometer particles | 盐城工学院 | 2017-05-31 | — | — | CN | disclosed |
| US-20140329221-A1 | REPERFUSION PROTECTION SOLUTION AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2014-11-06 | — | — | US | disclosed |
| WO-2013082458-A1 | REPERFUSION PROTECTION SOLUTION AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-06-06 | — | — | WO | disclosed |
| US-20060166360-A1 | Compositions, solutions, and methods used for transplantation | THE GENERAL HOSPITAL CORPORATION (US) | 2006-07-27 | — | — | US | disclosed |
| US-20040143025-A1 | Carbon monoxide generating compunds for treatment of vascular, inflammatory and immune disorders | SANGSTAT MEDICAL CORPORATION | 2004-07-22 | — | — | US | disclosed |
| WO-2004034887-A2 | COMPOSITIONS, SOLUTIONS, AND METHODS USED FOR TRANSPLANTATION | THE GENERAL HOSPITAL CORPORATION (US) | 2004-04-29 | — | — | WO | disclosed |
| EP-1381354-A2 | CARBON MONOXIDE GENERATING COMPOUNDS FOR TREATMENT OF VASCULAR, INFLAMMATORY AND IMMUNE DISORDERS | SANGSTAT MEDICAL CORPORATION (US) | 2004-01-21 | — | — | EP | disclosed |
| US-20030068387-A1 | Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders | SANGSTAT MEDICAL CORPORATION | 2003-04-10 | — | — | US | disclosed |
| WO-2002078684-A2 | CARBON MONOXIDE GENERATING COMPOUNDS FOR TREATMENT OF VASCULAR, INFLAMMATORY AND IMMUNE DISORDERS | SANGSTAT MEDICAL CORPORATION (US) | 2002-10-10 | — | — | WO | disclosed |